®: CRE Regulatory Action of the Week
EPA Finds "No Merit" in NTP Atrazine Review
Click for EPA's atrazine comments to NTP.
Click to Nominate Regulatory Action of the Week.
EPA has asked NTP to withdraw atrazine from review in NTP's 12th Report on Carcinogens. EPA's letter to NTP points out that EPA has just completed its own multi-year review of atrazine and cancer. Based on EPA's review of all the best available evidence, EPA concluded that atrazine is not likely to be a human carcinogen. No new evidence will be available until several years from now, when ongoing epidemiological studies will be completed. EPA itself intends to review atrazine again when the new epidemiological data become available. Consequently, EPA believes there is "no merit" in NTP's proposed cancer review of atrazine for the 12th RoC.